2022BEIRUTAPS: U.S. Embassy Beirut PAS Annual Program Statement
Closed
This grant is closed. A newer notice from the same program is open now: Austrian-American Partnership Fund (AAPF) (OFOP0002825). Status: Closes January 1, 2099 (26353 days left). It is in our archive of U.S. Mission to Lebanon notices from 2021.
U.S. Mission to Lebanon offered grants of up to $450,000 (at least $10,000) to nonprofits and colleges and universities. It expected to make about 10 awards worth $450,000 in total. Applications closed on September 1, 2022.
From the official notice on Grants.gov, last changed December 22, 2021. Checked November 7, 2026.
- Award ceiling$450,000
- Award floor$10,000
- Total funding$450,000
- Expected awards10
- Cost sharingNot required
- Funding typeCooperative Agreement, Grant
Key dates
| Posted | December 21, 2021 |
|---|---|
| Deadline | September 1, 2022 |
| Archived by Grants.gov | October 1, 2022 |
Who can apply
This opportunity was open to nonprofits and colleges and universities.
- Public and State controlled institutions of higher education
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
Is this a realistic fit?
- Past Public Diplomacy Programs awards averaged $26,570; this notice allows up to $450,000 per award.
- No cost sharing or match is required.
What the grant funds
PAS Lebanon invites proposals for programs that foster civic engagement on anti-corruption, inclusiveness, and good governance; showcasing U.S. values through capacity building and economic sustainment; English language study and programming; and supporting arts and culture programming. All programs must include an American cultural element, or connection with American expert(s), organization(s), or institution(s) in a specific field that will promote increased understanding of U.S. policy and perspectives.
Who has won Public Diplomacy Programs grants before
From fiscal 2021 to 2025, Public Diplomacy Programs (19.040) awarded $358 million across 13,489 grant awards, an average of $26,570 per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Miscellaneous Foreign Awardees | 2,478 | $50.3 million | |
| Meridian International Center | District of Columbia | 27 | $6.5 million |
| American Councils for International Education: Actr/Accels, Inc. | District of Columbia | 72 | $4.7 million |
| Cultural Vistas, Inc. | District of Columbia | 22 | $4.7 million |
| World Learning Inc. | Vermont | 25 | $4.4 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, OFOP0002825, which is open now.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is 2022BEIRUTAPS still open?
No. It closed on September 1, 2022. A newer notice is open: OFOP0002825, closes January 1, 2099 (26353 days left).
Who can apply for U.S. Embassy Beirut PAS Annual Program Statement?
U.S. Mission to Lebanon accepted applications from nonprofits and colleges and universities.
What is the deadline for U.S. Embassy Beirut PAS Annual Program Statement?
Closed September 1, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $450,000 each. About $450,000 in total across about 10 awards.
Who has won Public Diplomacy Programs grants before?
The largest recipients over five fiscal years were Miscellaneous Foreign Awardees, Meridian International Center, American Councils for International Education: Actr/Accels, Inc. The program made 13,489 awards worth $358 million in that time.
Similar open grants
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
- Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required)
- Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required)